BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, February 13, 2026
See today's BioWorld
Home
» Adventrx Acquires SynthRx, Revives Sickle Cell Drug P188
To read the full story,
subscribe
or
sign in
.
Adventrx Acquires SynthRx, Revives Sickle Cell Drug P188
Feb. 15, 2011
By
Tom Wall
Adventrx Pharmaceuticals Inc. is hoping to revive a sickle cell anemia drug that all but disappeared after a disappointing Phase III trial in 1999.
BioWorld
